Cargando…

Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 year

PURPOSE: The purpose of this study was to compare intravitreal ziv-aflibercept (IVZ) monotherapy to intravitreal bevacizumab (IVB) monotherapy in patients with exudative age-related macular degeneration (eAMD). MATERIALS AND METHODS: Patients with treatment-naïve eAMD treated with pro re nata (PRN)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Sumit Randhir, Parikh, Ravi, Sakurada, Yoichi, Uplanchiwar, Bhushan, Mansour, Ahmad, Goud, Abhilash, Modi, Yasha S., Chhablani, Jay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787097/ https://www.ncbi.nlm.nih.gov/pubmed/33437603 http://dx.doi.org/10.4103/tjo.tjo_3_20

Ejemplares similares

Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion
por: Braimah, Imoro Z, et al.
Publicado: (2019)

Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
por: Singh, Sumit Randhir, et al.
Publicado: (2019)

Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage
por: Mansour, Ahmad M., et al.
Publicado: (2020)

Ziv-aflibercept in macular disease
por: Mansour, Ahmad M, et al.
Publicado: (2015)

Retinal pigment epithelium rip following single intravitreal ziv-aflibercept injection
por: Singh, Sumit Randhir, et al.
Publicado: (2018)

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2017)

Regression in polypoidal choroidal vasculopathy treated with ziv-aflibercept monotherapy – short term study
por: Mishra, Sai B., et al.
Publicado: (2022)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose, Remya, et al.
Publicado: (2016)

One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion
por: Eldeeb, Mohab, et al.
Publicado: (2017)

Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
por: Chhablani, Jay
Publicado: (2015)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
por: Kikushima, Wataru, et al.
Publicado: (2021)

Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration
por: Kikushima, Wataru, et al.
Publicado: (2017)

Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population
por: Braimah, Imoro Zeba, et al.
Publicado: (2022)

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept
por: Mansour, Ahmad M, et al.
Publicado: (2019)

Ziv-aflibercept in metastatic colorectal cancer
por: Patel, Anuj, et al.
Publicado: (2013)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
por: Kikushima, Wataru, et al.
Publicado: (2023)

Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration
por: Shijo, Taiyo, et al.
Publicado: (2020)

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture
por: Malik, Deepika, et al.
Publicado: (2014)

Ziv-Aflibercept Use in Metastatic Colorectal Cancer
por: Rodriguez, Mabel
Publicado: (2013)

Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2016)

Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection
por: Nawar, Amin E., et al.
Publicado: (2022)

Comment on: Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
por: Sen, Alok, et al.
Publicado: (2015)

Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes
por: Moradian, Siamak, et al.
Publicado: (2023)

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike, Naoko, et al.
Publicado: (2019)

Intravitreal Ziv-Aflibercept versus Bevacizumab for Naïve Central Retinal Vein Occlusion with Macular Edema: An Interim Analysis of a Randomized Non-Inferiority Trial
por: Sinawat, Suthasinee, et al.
Publicado: (2023)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
por: Lee, Junyeop, et al.
Publicado: (2022)

Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study
por: Rowe, Lucas W., et al.
Publicado: (2023)

Retinal Toxicity of Intravitreal Injection of Ziv-Aflibercept in Albino Rabbits
por: Ramon, Dan, et al.
Publicado: (2018)

Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients
por: Nawar, Amin E., et al.
Publicado: (2020)

The sterility, stability and efficacy of repackaged ziv-aflibercept for intravitreal administration
por: Juhong, Jakkrit, et al.
Publicado: (2022)

Clinical and genetic characteristics of pachydrusen in patients with exudative age-related macular degeneration
por: Fukuda, Yoshiko, et al.
Publicado: (2019)

The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
por: Unsal, Erkan, et al.
Publicado: (2018)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases
por: HodjatJalali, Kamran, et al.
Publicado: (2017)

Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation
por: Hermosilla, Jesús, et al.
Publicado: (2020)

Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Yoneyama, Seigo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ijm87dtkjo98ia2nf2culfnvf7